Orthofix Med Inc Stock Price, News & Analysis

Orthofix Medical Inc. (NASDAQ:OFIX) announced five-year data from the M6-C artificial cervical disc IDE study, revealing significant benefits over anterior cervical discectomy and fusion (ACDF) in reducing neck disability and pain. Presented at the ISASS annual meeting on June 3, results show a mean Neck Disability Index improvement of 47.5 points for M6-C patients versus 33.4 for ACDF. The M6-C group also reported a low revision surgery rate of 3.1%, indicating strong clinical efficacy. The study aims to continue collecting data, supporting its safety and performance in spinal procedures.

Orthofix Medical Inc. (NASDAQ:OFIX) announced that CEO Jon Serbousek and CFO Doug Rice will present at the UBS Global Healthcare investor conference on May 23, 2022, at 2:45 p.m. ET. The event will be held at the Lotte New York Palace in New York City and will be available for live streaming and replay on the company’s website for up to one year. Orthofix specializes in spinal and orthopedic devices, aiming to enhance patient mobility through innovative solutions distributed in over 60 countries.

Orthofix Medical reported Q1 2022 net sales of $106.4 million, marking a 1% increase year-over-year. The rise was fueled by new product innovations, particularly in Biologics, Spinal Implants, and Orthopedics. Despite facing challenges like COVID-19 and global supply chain issues, the company received FDA approvals for AccelStim and TrueLok™ EVO. The net loss narrowed to $(4.5) million from $(5.8) million in the prior year. Adjusted EBITDA dropped to $7.1 million. For 2022, the company anticipates net sales between $475 million and $490 million, with expected growth in constant currency.

Orthofix Medical Inc. (NASDAQ:OFIX) has received FDA pre-market approval for its AccelStim™ bone healing therapy, a Class III device aimed at treating fresh fractures and nonunions. The AccelStim device employs Low-Intensity Pulsed Ultrasound (LIPUS) to promote natural bone healing. Commercial launch is expected in Q2 2023, targeting a $100 million market for LIPUS solutions. This advancement positions Orthofix as a leader in bone growth stimulation, offering both PEMF and LIPUS devices.

Orthofix Medical Inc (NASDAQ:OFIX) announces the renewal of its exclusive partnership with MTF Biologics, extending marketing rights to the Trinity^™ allograft line through 2032. The agreement also includes the development of a new demineralized bone matrix (DBM) under the Legacy^™ brand. This aims to enhance Orthofix's portfolio and offers expanded treatment options for patients. The Legacy DBM is expected to be available in Q3 2022. Both companies emphasize their commitment to innovative solutions in orthopedic and spine surgical applications.

Orthofix Medical Inc. (NASDAQ:OFIX) will release its Q1 2022 financial results on May 6, 2022, before the market opens. A conference call, led by President Jon Serbousek and CFO Doug Rice, will discuss the results at 8:30 a.m. ET the same day. Participants can access the call by dialing the respective numbers in the U.S., Canada, and other locations, using the access code 428610. Additionally, a replay will be available for three weeks. Orthofix focuses on innovative medical device solutions in the spine and orthopedic markets.

Orthofix Medical Inc (NASDAQ:OFIX) has appointed Kimberley Elting as President of its Global Orthopedics business. Elting, who has over 25 years of experience in the medical device industry, succeeds Paul Gonsalves. The leadership change is expected to drive growth in Orthofix's orthopedic sector, which is crucial to the company's mission of providing innovative solutions for improving patient mobility. Elting's background includes significant roles in corporate development and business growth within Orthofix and other firms.

Orthofix Medical Inc (NASDAQ: OFIX) has received FDA 510(k) clearance for its TrueLok EVO Ring Fixation System, designed for complex limb reconstruction and deformity corrections. This system stands out as the only circular fixator featuring radiolucent rings and struts, enhancing visibility during surgeries. Its preassembled sterile packaging aims to simplify surgical procedures. The TrueLok EVO is applicable for various orthopedic treatments in both adults and children, excluding newborns. The launch is part of Orthofix's commitment to improving patient mobility and outcomes.

Orthofix Medical reported fourth-quarter net sales of $125.1 million, a 6% increase year-over-year. For fiscal year 2021, net sales reached $464.5 million, up 14% from 2020. The company demonstrated strong growth in both global spinal implants and orthopedics, driven by products like the M6-C™ cervical disc. However, the net loss increased to $(32.8) million in Q4, with an adjusted EPS of $0.27. The 2022 outlook estimates net sales between $475 million and $490 million, indicating modest year-over-year growth.